| Summary: | Undergoing an era of revolutionary new knowledge and advances
in the systemic and surgical treatment of peritoneally disseminated epithelial ovarian cancer (EOC), we never before have been
confronted with such a plethora of novel targeted agents, genetically based treatment strategies and cutting edge surgical techniques that enrich our armamentarium in the fight against this
deadly disease [1–3]. Still, our art as clinicians is to put all this
new body of knowledge into the right context so that we can help
our patients without compromising their care through an enthusiastic effort of implementing new therapeutic
|
|---|